RVMD: financial statements from SEC — TradeAlmanac

RVMD

Revolution Medicines, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Mar 31, 2026	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Sep 30, 2024	Jun 30, 2024
Revenue	—	—	—	—	0	0
Research and development	344m	263m	224m	206m	152m	135m
Selling, general and administrative	101m	53m	41m	35m	24m	22m
Operating expenses	445m	315m	265m	241m	176m	157m
Operating income	−445m	−315m	−265m	−241m	−176m	−157m
Pre-tax income	−454m	−305m	−248m	−213m	−156m	−133m
Income tax	—	—	—	—	0	0
Net income	−454m	−305m	−248m	−213m	−156m	−133m
Earnings per share	−2.29	−1.61	−1.31	−1.13	−0.94	−0.81
Earnings per share, diluted	−2.29	−1.61	−1.31	−1.13	−0.94	−0.81
Weighted average shares	198m	189m	189m	188m	167m	165m
Weighted average shares, diluted	198m	189m	189m	188m	167m	165m

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	441m	384m	217m	402m	334m	543m	201m	276m
Short-term investments	1.47bn	1.64bn

Cash flow

Metric	Mar 31, 2026	Mar 31, 2025	Sep 30, 2024	Jun 30, 2024
Operating cash flow	−354m	−194m	—	—
Depreciation and amortisation	2m	2m	2m	2m
Share-based compensation	87m	25m	—

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)